Company intelligence / Profile preview

CKP Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

CKP Therapeutics focuses on developing innovative treatments for refractory advanced cancers by targeting cancer stem cells. Their research has identified SERCA as a critical target in therapy-resistant PTC and developed novel SERCA inhibitors that have shown substantial tumor reduction in patient-derived xenograft models. These findings suggest potential for clinically meaningful progress in treating refractory cancers

Therapeutic areas: Oncology
Modalities: Novel small moleculescombination therapies
Industry: Biotech

Drug pipeline

2 assets

candidate 33

Pre-clinical

Indications: Sorafenib-resistant papillary thyroid cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on CKP Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKP Therapeutics.

Explore the full profile